Catalyst Dossier · compiled by CeliA 🧫

MEDICAL PROPERTIES TRUST INC (MPW)

Biotechnology · market cap $3.0B

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Relaxin	Phase 3	Heart Failure, Congestive
Tavokinogene Telseplasmid (tavo)	Phase 2	Melanoma
Oxytocin 100 i.u.	Phase 2	Vaginal Atrophy
Isoflurane	Phase 3	Sedation
Oxytocin 400 IU vaginal gel	Phase 2	Vulvovaginal Atrophy
Aramchol	Phase 2	Non-Alcoholic Fatty Liver Disease
Ibuprofen and Aprepitant	Phase 3	Primary Dysmenorrhea
Sevre-Long™	Phase 3	Opiate Dependent
Oxytocin	Phase 2	Atrophy
Midazolam	Phase 3	Sedation
FX06	Phase 2	Myocardial Ischemia
Active Theramine and Active Naproxen	Phase 3	Low Back Pain
GDC 268 Lotion	Phase 3	Acne Vulgaris
low-dose group (naltrexone implant 0.9 g + general supportive psychological counseling)	Phase 2	AUD
IVACFLU-S	Phase 3	Influenza, Human
GDC-229	Phase 3	Bacterial Vaginosis
EPODURE (dermal Biopump for erythropoietin)	Phase 2	Anemia
Tadalafil 5mg (Male)	Phase 3	Erectile Dysfunction
Glyceryl trinitrate	Phase 2	Erectile Dysfunction
Osteodex	Phase 2	Prostate Cancer Metastatic

Price & technical context

3-month

+3.3%

6-month

+21.8%

12-month

+14.1%

52-wk range

$3.98–$6.21

vs 50-day MA

-4.1%

vs 200-day MA

+3.4%

Realized vol

40.4%

Max drawdown

-41.6%

Daily closes through 2026-01-30. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for MPW (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.